Anticancer drug sensitivity testing using an oxygen electrode apparatus

Suzuki, Minako; Ishikawa, Hiroshi; Tanaka, Akira; Mataga, Izumi

doi:10.1111/j.1749-0774.2010.00092.x

Cited by 3 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Takahashi et al reported that the sensitivity of NOCS-1 cell lines established from mandibular gingival carcinoma and cell lines established by xenotransplantation of the cell lines were similar in anticancer drug susceptibility tests 28) . However, in all previous reports, the sensitivity of anticancer drugs is limited to single agents 28,29) . In the case of clinical administration, administer a combination of multiple drugs.…”

Section: Discussionmentioning

confidence: 99%

“…The anticancer drug sensitivity of CDDP + 5-FU + DOC under normal contact concentrations was 10.8% for the T/C% of the primary tumor, 8.6% for NOKT-1, and 37.4% for NOKT-1-XG. Suzuki et al established cell lines from 15 patients with papillary tubular cancer and compared their susceptibility with that of primary tumors using anticancer drug susceptibility tests 29) . The cell lines and primary tumors demonstrated consistent susceptibility in 13 patients, while the primary tumor and established cell lines exhibited different sensitivities in 2 patients 29) .…”

Section: Discussionmentioning

confidence: 99%

“…Suzuki et al established cell lines from 15 patients with papillary tubular cancer and compared their susceptibility with that of primary tumors using anticancer drug susceptibility tests 29) . The cell lines and primary tumors demonstrated consistent susceptibility in 13 patients, while the primary tumor and established cell lines exhibited different sensitivities in 2 patients 29) . From this report, it can be assumed that the primary tumor and the established cell line do not necessarily exhibit the same susceptibility.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Establishment and Characterization of the Human Tongue Squamous Cell Carcinoma Cell Line NOKT-1

Sakuma

Takahashi

Kii

et al. 2021

J. Hard Tissue Biology.

Self Cite

View full text Add to dashboard Cite

The squamous cell carcinoma cell line NOKT-1 was successfully established from the right tongue of a 74-yearold Japanese man. Pathological diagnosis of the original tumor was moderately differentiated squamous cell carcinoma. NOKT-1 cells were transplanted subcutaneously into nude mice and xenograft was formed. In addition, the NOKT-1-XG cell line was established from the transplanted tumor of NOKT-1 cells. NOKT-1 cells and NOKT-1-XG cells were epithelial neoplastic and pleomorphic cells, which were similar. Immunocytochemistry revealed that NOKT-1 and NOKT-1-XG cells were CK17 and human mitochondria positive. To authenticate the NOKT-1 cell line and NOKT-1-XG cell line, we examined cross-contamination with other cell lines using short tandem repeat analysis, the results of which showed that NOKT-1 and NOKT-1-XG are new cell lines. Four of the 16 loci, corresponding to 25%, were different between these two cell lines, which indicates that the NOKT-1 genome was altered by transplantation. Moreover, in AM, NOKT-1 did not have a Y chromosome, whereas NOKT-1-XG had. Despite the genetic differences, a collagen gel droplet-embedded culture drug susceptibility test demonstrated that NOKT-1 cells derived from the original tumor and the NOKT-1-XG cell line had the same sensitivity. This cell line could be very useful for the development of immunotherapy and chemotherapy regimens and research on cancer etiology.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Establishment and Characterization of the Human Tongue Squamous Cell Carcinoma Cell Line NOKT-1

Sakuma

Takahashi

Kii

et al. 2021

J. Hard Tissue Biology.

Self Cite

View full text Add to dashboard Cite

show abstract

“…All experiments were approved by the Institutional Ethics Committee of the School of Life Dentistry at Niigata, Nippon Dental University, and informed consents were obtained. Anticancer drug sensitivity testing using an oxygen electrode apparatus Anticancer drug sensitivity testing was carried out using the oxygen electrode apparatus described by the authors in a previous report and using the same evaluation method [11,12]. For the oxygen electrode apparatuses, we used the CT&C precision oxygen electrode apparatus (Aloka Co., Ltd.), which is capable of measuring single samples of a small number of cells, the DOX-10 (Daikin Industries, Ltd.), which is capable of measuring 10 samples using 2 9 10 6 cells/well, the DOX-24 (Aloka Co., Ltd.), which can measure 24 samples using 2 9 10 6 cells/well, and the DOX-96 (Daikin Industries, Ltd.), which can measure 96 samples using 2 9 10 5 cells/well.…”

Section: Culture Methodsmentioning

confidence: 99%

Heterogeneity of anticancer drug sensitivity in squamous cell carcinoma of the tongue

et al. 2010

Self Cite

View full text Add to dashboard Cite

Heterogeneity is known to be present to varying degrees in cancer cell groups. There have been no reports, however, of studies in which a single cell clone was prepared from a cancer cell group to examine heterogeneity with respect to anticancer drug sensitivity. Thus, the authors herein report an investigation into the heterogeneity of cancer cells within the same tumor with respect to anticancer drug sensitivity. Anticancer drug sensitivity was investigated in primary tumors, metastatic lymph node tumors, recurrent tumors and established cell lines obtained from four cases of tongue cancer using an oxygen electrode apparatus. As differences were observed in anticancer drug sensitivity from one case to another, even though all four were of the same pathological tissue type, the individual differences were apparently significant. Moreover, primary tumors and recurrent tumors demonstrated different sensitivities to the anticancer drugs even in the same patient. When single cell clones were prepared from primary tumors and anticancer drug sensitivity testing was carried out, sensitivity to anticancer drugs that was not seen in the primary tumors was observed. We performed RT-PCR on cell groups derived from this single cell using MDR1, MRP1, MRP2 and ERCC1, which are primary genes that are resistant to anticancer drugs. Expression of MDR and ERCC1 was not observed in single cell clones nos. 1-10. MRP1 and MRP2, on the other hand, were expressed in all of these single cell clones. Because cells with different sensitivity levels were initially present in the cancer cell groups, even when large numbers of cancer cells died in response to anticancer drug therapy, the results suggest the possibility that recurrence and metastasis occur based on cells with differing sensitivities. After examining anticancer drug sensitivity at the single cell level, we believe that anticancer drug-resistant genes may be involved in the heterogeneity of anticancer drug sensitivity with respect to cancer cell groups.

show abstract

“…As a part of the precision medicine program, drug sensitivity screening has been more and more widely applied in recent years [ 11 , 12 ]. Although sensitive drugs of all the cancers could be screened theoretically, factors like finite cell number, the lack of tumor biopsy, and the high degree of heterogeneity in the tumor often result in unsatisfied clinical outcomes.…”

Section: Introductionmentioning

confidence: 99%

Application of High-Efficiency Cell Expansion and High-Throughput Drug Sensitivity Screening for Leukemia Treatment

Wang

et al. 2022

Disease Markers

View full text Add to dashboard Cite

This study is to assess the clinical value of in vitro primary cell high-efficiency expansion and high-throughput drug sensitivity screening (HEHDS) system in leukemia, and we evaluated a cohort of 121 patients with acute myeloid leukemia (AML) and 27 patients with acute lymphoblastic leukemia (ALL) using HEHDS. Bone marrow aspirates were collected from patients with leukemia. Purified leukemic cancer cells were obtained, cultured, and screened with a panel of 247 FDA-approved compounds by HEHDS technology. Ninety-six patients received HEHDS-guided therapy while 52 patients who were subjected to physician directed therapy served as controls. ALL patients who received treatment guided by HEHDS showed higher rate of complete remission (CR) than that of patients in the non-HEHDS group (90.91% vs. 56.25%). Similarly, AML patients received HEHDS-guided therapy were found to have greater CR rate, when compared with patients who received physician-directed therapy (45.88% vs. 25%). There was a significantly higher rate of CR in HEHDS-guided therapy group compared to the non-HEHDS group. The application of HEHDS could be beneficial for leukemia treatment.

show abstract

Anticancer drug sensitivity testing using an oxygen electrode apparatus

Cited by 3 publications

References 11 publications

Establishment and Characterization of the Human Tongue Squamous Cell Carcinoma Cell Line NOKT-1

Establishment and Characterization of the Human Tongue Squamous Cell Carcinoma Cell Line NOKT-1

Heterogeneity of anticancer drug sensitivity in squamous cell carcinoma of the tongue

Application of High-Efficiency Cell Expansion and High-Throughput Drug Sensitivity Screening for Leukemia Treatment

Contact Info

Product

Resources

About